The Miami Entrepreneur

Regeneron shares fall after FDA rejects high-dose eye disease treatment

Read Time:6 Second

Regeneron said the rejection was “solely due to an ongoing review of inspection findings at a third-party filler.”

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Stocks Advance After Data Highlights Resilient Economy
Next post : Justice Department, FTC toughen merger guidelines